These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 23150701)
41. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118 [TBL] [Abstract][Full Text] [Related]
42. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391 [TBL] [Abstract][Full Text] [Related]
43. Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases? Lubezky N; Geva R; Shmueli E; Nakache R; Klausner JM; Figer A; Ben-Haim M World J Surg; 2009 May; 33(5):1028-34. PubMed ID: 19234865 [TBL] [Abstract][Full Text] [Related]
44. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828 [TBL] [Abstract][Full Text] [Related]
45. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062 [TBL] [Abstract][Full Text] [Related]
46. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases. Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708 [TBL] [Abstract][Full Text] [Related]
47. Feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study. Kataoka K; Kanazawa A; Nakajima A; Yamaguchi A; Arimoto A; Kohno Y Surg Today; 2013 Oct; 43(10):1154-61. PubMed ID: 23139049 [TBL] [Abstract][Full Text] [Related]
48. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002 [TBL] [Abstract][Full Text] [Related]
49. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Rubbia-Brandt L; Giostra E; Brezault C; Roth AD; Andres A; Audard V; Sartoretti P; Dousset B; Majno PE; Soubrane O; Chaussade S; Mentha G; Terris B Ann Oncol; 2007 Feb; 18(2):299-304. PubMed ID: 17060484 [TBL] [Abstract][Full Text] [Related]
50. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378 [TBL] [Abstract][Full Text] [Related]
51. Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab. Vera R; Gomez Dorronsoro M; Lopez-Ben S; Viudez A; Queralt B; Hernandez I; Ortiz-Duran MR; Zazpe C; Soriano J; Amat I; Herrera Cabezón J; Diaz E; Codina-Barreras A; Hernandez-Yagüe X; Quera A; Figueras J Clin Transl Oncol; 2014 Aug; 16(8):739-45. PubMed ID: 24338508 [TBL] [Abstract][Full Text] [Related]
52. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases. Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295 [TBL] [Abstract][Full Text] [Related]
53. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy. Popov I; Milicević M; Radosević-Jelić Lj Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134 [TBL] [Abstract][Full Text] [Related]
54. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. Saif MW World J Gastroenterol; 2009 Aug; 15(31):3855-64. PubMed ID: 19701965 [TBL] [Abstract][Full Text] [Related]
55. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Neeff HP; Drognitz O; Klock A; Illerhaus G; Opitz OG; Hopt UT; Makowiec F Int J Colorectal Dis; 2012 May; 27(5):635-45. PubMed ID: 22139030 [TBL] [Abstract][Full Text] [Related]
56. Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy. Knowles B; Welsh FK; Chandrakumaran K; John TG; Rees M HPB (Oxford); 2012 May; 14(5):298-309. PubMed ID: 22487067 [TBL] [Abstract][Full Text] [Related]
57. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604 [TBL] [Abstract][Full Text] [Related]
58. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584 [TBL] [Abstract][Full Text] [Related]
59. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer. Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S; Oncology; 2013; 84(1):14-21. PubMed ID: 23076023 [TBL] [Abstract][Full Text] [Related]
60. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab. Basso M; Dadduzio V; Ardito F; Lombardi P; Strippoli A; Vellone M; Orlandi A; Rossi S; Cerchiaro E; Cassano A; Giuliante F; Barone C Medicine (Baltimore); 2016 May; 95(20):e3722. PubMed ID: 27196492 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]